119 related articles for article (PubMed ID: 12746450)
1. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity.
Chiara F; Michieli P; Pugliese L; Comoglio PM
J Biol Chem; 2003 Aug; 278(31):29352-8. PubMed ID: 12746450
[TBL] [Abstract][Full Text] [Related]
2. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).
Longati P; Bardelli A; Ponzetto C; Naldini L; Comoglio PM
Oncogene; 1994 Jan; 9(1):49-57. PubMed ID: 8302603
[TBL] [Abstract][Full Text] [Related]
3. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
5. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
6. Activating mutations for the met tyrosine kinase receptor in human cancer.
Jeffers M; Schmidt L; Nakaigawa N; Webb CP; Weirich G; Kishida T; Zbar B; Vande Woude GF
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11445-50. PubMed ID: 9326629
[TBL] [Abstract][Full Text] [Related]
7. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
Peschard P; Ishiyama N; Lin T; Lipkowitz S; Park M
J Biol Chem; 2004 Jul; 279(28):29565-71. PubMed ID: 15123609
[TBL] [Abstract][Full Text] [Related]
8. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
9. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between the proto-oncogenes Met and Ron.
Follenzi A; Bakovic S; Gual P; Stella MC; Longati P; Comoglio PM
Oncogene; 2000 Jun; 19(27):3041-9. PubMed ID: 10871856
[TBL] [Abstract][Full Text] [Related]
11. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.
Bardelli A; Longati P; Gramaglia D; Basilico C; Tamagnone L; Giordano S; Ballinari D; Michieli P; Comoglio PM
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14379-83. PubMed ID: 9826708
[TBL] [Abstract][Full Text] [Related]
12. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
14. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
15. Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling.
Jeffers MF; Vande Woude GF
Oncogene; 1999 Sep; 18(36):5120-5. PubMed ID: 10490849
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.
Miller M; Ginalski K; Lesyng B; Nakaigawa N; Schmidt L; Zbar B
Proteins; 2001 Jul; 44(1):32-43. PubMed ID: 11354004
[TBL] [Abstract][Full Text] [Related]
17. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein.
Lamorte L; Kamikura DM; Park M
Oncogene; 2000 Dec; 19(52):5973-81. PubMed ID: 11146548
[TBL] [Abstract][Full Text] [Related]
18. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
19. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase.
Rodrigues GA; Park M
Mol Cell Biol; 1993 Nov; 13(11):6711-22. PubMed ID: 8413267
[TBL] [Abstract][Full Text] [Related]
20. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]